| Added by | andrei.turtoi |
|---|---|
| Last modified by | standudu |
| Group name | EquipeAT |
| Item Type | Journal Article |
| Title | Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy |
| Creator | Neron et al. |
| Author | Mathias Neron |
| Author | Arnaud Guille |
| Author | Pierre-Emmanuel Colombo |
| Author | Cristina Leaha |
| Author | José Adelaide |
| Author | Nadine Carbuccia |
| Author | Frédéric Courtier |
| Author | Evelyne Crapez |
| Author | Michel Fabbro |
| Author | Sébastien Gouy |
| Author | Emilie Mamessier |
| Author | Daniel Birnbaum |
| Author | François Bertucci |
| Author | Max Chaffanet |
| Abstract | Hormone therapy (HT) is an effective treatment for metastatic endometrial carcinoma (mEC), with limited toxicity and low cost. We focused on molecular analysis of mECs treated by HT and, for the first time to date, we compared the genomic profiles of paired metastasis and primary ECs. The main objective was to identify predictive factors of the response to HT as well as specific altered signaling pathways driving mEC biology. From 1052 patients with EC treated by HT in two French cancer centers, 32 with endometrioid EC and 6 with high grade serous EC were included. We evaluated hormone receptors (HR) and mismatch repair proteins expression by immunohistochemistry and gene alterations by targeted next-generation sequencing and array-based comparative genomic hybridization. Several variables were tested in univariate and multivariate analyses to identify potential associations with (i) the clinical benefit of HT (CBHT) and (ii) a longer response (>18 months) (LRHT) and overall survival (OS). We compared the biological and genomic profiles of 11 primary/metastatic EC pairs. Thirty tumors (78.9%) were HR-positive and 6 (15.8%) showed microsatellite instability (MSI). The genomic profiles of 34 tumors showed an average altered genome of 3.26%, DNA repair homologous recombination deficiency in five tumors (14.7%), and 17 regions significantly targeted by amplification/deletion. Thirty-three tumors had 273 variants (158 genes, median of 7 mutations/sample), including 112 driver mutations. TP53, PTEN, PPP2R1A, ARID1A, FGFR2, and PIK3CA were the most frequently mutated. Based on the genomic status, nine oncogenic pathways were altered in more than 25% of primary EC. Clinically, 22 (57.9%) and 6 (15.8%) patients presented CBHT and LRHT, respectively. Neither oncogenic pathways alterations nor the variables tested were associated with CBHT and LRHT. Only patient's age, mitotic index and the presence of at least one HR were associated with OS. Paired analysis of the primary/metastatic samples showed that among the 22 mutations acquired in the metastatic counterparts, the most frequently targeted genes were involved in pathways that might confer a selective advantage to cancer metastasis including hormone resistance. In conclusion, only patient's age, mitotic index and the presence of at least one HR were associated with OS. The identification of gene mutations newly acquired in metastasis might help to better understand the formation of EC metastasis and select the best actionable candidates for HT-treated patients at the metastatic stage. |
| Publication | Journal of Personalized Medicine |
| Volume | 12 |
| Issue | 5 |
| Pages | 655 |
| Date | 2022-04-19 |
| Journal Abbr | J Pers Med |
| Language | eng |
| DOI | 10.3390/jpm12050655 |
| ISSN | 2075-4426 |
| Library Catalog | PubMed |
| Extra | PMID: 35629078 PMCID: PMC9143816 |
| Tags | copy number alterations, first, first-last-corresponding, metastatic endometrial carcinoma, mutations, original, protein expression |
| Date Added | 2022/08/30 - 10:50:37 |
| Date Modified | 2022/08/30 - 16:44:29 |
| Notes and Attachments | Full Text (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
